MedTrace Logo

A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors

NCT04761198 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2025-03-17

Study results available
· View outcomes & findings →

Summary

This is an open-label, phase 1b/2, multicenter study designed to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of etigilimab in combination with nivolumab in participants with locally advanced or metastatic solid tumors. Participants will be assigned to receive etigilimab (every 2 weeks) in combination with nivolumab (240 milligrams \[mg\] every 2 weeks).

Conditions

  • Solid Tumor, Adult
  • Advanced Solid Tumor
  • Metastatic Solid Tumor

Interventions

DRUG

Etigilimab

IV infusion of IV etigilimab every 2 weeks

DRUG

Nivolumab

IV infusion of nivolumab every 2 weeks

Sponsors & Collaborators

  • ICON Clinical Research

    collaborator INDUSTRY

  • Mereo BioPharma

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-23
Primary Completion
2023-10-30
Completion
2023-10-30
FDA Drug
Yes

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04761198 on ClinicalTrials.gov